A concern regarding the upcoming androgen degrader drug GT20029 Chat 1/25/2025
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
View this post in the Community →
Similar Community Posts Join
5 / 256 resultscommunity Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community It’s over. NOTHING has worked.
A user who has been trying various treatments for hair loss for four years, with no success. Suggestions include use of minoxidil, finasteride, RU58841, microneedling, supplements and multivitamins, lifestyle changes, scalp biopsy, and SMP.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Related Research
6 / 7 results
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.